Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
Abstract Background The survival rate of adult patients with Hodgkin lymphoma (HL) depends on the responses to standard chemotherapy, radiotherapy, or combined therapy. Resource‐limited countries face numerous obstacles in supporting patients with HL who undergo chemotherapy, especially in advanced...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1839 |
| _version_ | 1828718055291617280 |
|---|---|
| author | Tawatchai Suwanban Supat Chamnanchanunt Pravinwan Thungthong Chajchawan Nakhahes Kunapa Iam‐arunthai Tananchai Akrawikrai Udomsak Bunworasate |
| author_facet | Tawatchai Suwanban Supat Chamnanchanunt Pravinwan Thungthong Chajchawan Nakhahes Kunapa Iam‐arunthai Tananchai Akrawikrai Udomsak Bunworasate |
| author_sort | Tawatchai Suwanban |
| collection | DOAJ |
| description | Abstract Background The survival rate of adult patients with Hodgkin lymphoma (HL) depends on the responses to standard chemotherapy, radiotherapy, or combined therapy. Resource‐limited countries face numerous obstacles in supporting patients with HL who undergo chemotherapy, especially in advanced stages. Aim To analyze the survival outcomes of adult patients with HL after combined‐modality treatment (CMT) with involved‐field or non‐involved‐field radiotherapy. Methods and Results We retrospectively reviewed the medical records of 90 adult patients with HL who received CMT at Rajavithi Hospital, Bangkok between 2007 and 2021. Patients with stage I‐IV disease received different therapies depending on their risk group. The risk groups were evaluated according to initial response, bulky disease, and B symptoms. Patients (n = 90) who underwent CMT were followed up for 34.7 months (range, 1–141 months). The median follow‐up periods of early and advanced‐stage patients were 53.1 months and 23.5 months, respectively. The estimated 5‐year overall survival (OS) and progression‐free survival (PFS) rates of patients with advanced‐stage diseases were 85% and 62%, respectively. There was a difference in the 3‐year overall survival among advance‐stage patients who underwent ABVD (94%) compared to those administered BEACOPPesc (50%), and the 3‐year PFS (84%) among patients who underwent ABVD was higher than that among those administered BEACOPPesc (66%). Radiotherapy increased toxicity but did not improve the survival rate. Conclusion Chemotherapy administered to patients with advanced‐stage adult HL was more effective than BEACOPPesc when ABVD was administered. Our findings are relevant for hospitals with limited resources. |
| first_indexed | 2024-03-12T14:37:16Z |
| format | Article |
| id | doaj.art-82fb85624e7e49b8916e968b1328f1d2 |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-03-12T14:37:16Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-82fb85624e7e49b8916e968b1328f1d22023-08-17T03:11:27ZengWileyCancer Reports2573-83482023-08-0168n/an/a10.1002/cnr2.1839Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational studyTawatchai Suwanban0Supat Chamnanchanunt1Pravinwan Thungthong2Chajchawan Nakhahes3Kunapa Iam‐arunthai4Tananchai Akrawikrai5Udomsak Bunworasate6Division of Hematology, Department of Medicine, Rajavithi Hospital College of Medicine, Rangsit University Bangkok ThailandDivision of Hematology, Department of Medicine, Rajavithi Hospital College of Medicine, Rangsit University Bangkok ThailandDivision of Hematology, Department of Medicine, Rajavithi Hospital College of Medicine, Rangsit University Bangkok ThailandDivision of Hematology, Department of Medicine, Rajavithi Hospital College of Medicine, Rangsit University Bangkok ThailandDivision of Hematology, Department of Medicine, Rajavithi Hospital College of Medicine, Rangsit University Bangkok ThailandDivision of Hematology, Department of Medicine, Rajavithi Hospital College of Medicine, Rangsit University Bangkok ThailandDivision of Hematology, Department of Medicine, Faculty of Medicine Chulalongkorn University Bangkok ThailandAbstract Background The survival rate of adult patients with Hodgkin lymphoma (HL) depends on the responses to standard chemotherapy, radiotherapy, or combined therapy. Resource‐limited countries face numerous obstacles in supporting patients with HL who undergo chemotherapy, especially in advanced stages. Aim To analyze the survival outcomes of adult patients with HL after combined‐modality treatment (CMT) with involved‐field or non‐involved‐field radiotherapy. Methods and Results We retrospectively reviewed the medical records of 90 adult patients with HL who received CMT at Rajavithi Hospital, Bangkok between 2007 and 2021. Patients with stage I‐IV disease received different therapies depending on their risk group. The risk groups were evaluated according to initial response, bulky disease, and B symptoms. Patients (n = 90) who underwent CMT were followed up for 34.7 months (range, 1–141 months). The median follow‐up periods of early and advanced‐stage patients were 53.1 months and 23.5 months, respectively. The estimated 5‐year overall survival (OS) and progression‐free survival (PFS) rates of patients with advanced‐stage diseases were 85% and 62%, respectively. There was a difference in the 3‐year overall survival among advance‐stage patients who underwent ABVD (94%) compared to those administered BEACOPPesc (50%), and the 3‐year PFS (84%) among patients who underwent ABVD was higher than that among those administered BEACOPPesc (66%). Radiotherapy increased toxicity but did not improve the survival rate. Conclusion Chemotherapy administered to patients with advanced‐stage adult HL was more effective than BEACOPPesc when ABVD was administered. Our findings are relevant for hospitals with limited resources.https://doi.org/10.1002/cnr2.1839adultadvance‐stage cancerchemotherapyHodgkin diseaselife expectancylimited resource country |
| spellingShingle | Tawatchai Suwanban Supat Chamnanchanunt Pravinwan Thungthong Chajchawan Nakhahes Kunapa Iam‐arunthai Tananchai Akrawikrai Udomsak Bunworasate Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study Cancer Reports adult advance‐stage cancer chemotherapy Hodgkin disease life expectancy limited resource country |
| title | Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study |
| title_full | Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study |
| title_fullStr | Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study |
| title_full_unstemmed | Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study |
| title_short | Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study |
| title_sort | survival rates of adult patients with hodgkin lymphoma who underwent abvd versus escalated beacopp in a resource limited country an observational study |
| topic | adult advance‐stage cancer chemotherapy Hodgkin disease life expectancy limited resource country |
| url | https://doi.org/10.1002/cnr2.1839 |
| work_keys_str_mv | AT tawatchaisuwanban survivalratesofadultpatientswithhodgkinlymphomawhounderwentabvdversusescalatedbeacoppinaresourcelimitedcountryanobservationalstudy AT supatchamnanchanunt survivalratesofadultpatientswithhodgkinlymphomawhounderwentabvdversusescalatedbeacoppinaresourcelimitedcountryanobservationalstudy AT pravinwanthungthong survivalratesofadultpatientswithhodgkinlymphomawhounderwentabvdversusescalatedbeacoppinaresourcelimitedcountryanobservationalstudy AT chajchawannakhahes survivalratesofadultpatientswithhodgkinlymphomawhounderwentabvdversusescalatedbeacoppinaresourcelimitedcountryanobservationalstudy AT kunapaiamarunthai survivalratesofadultpatientswithhodgkinlymphomawhounderwentabvdversusescalatedbeacoppinaresourcelimitedcountryanobservationalstudy AT tananchaiakrawikrai survivalratesofadultpatientswithhodgkinlymphomawhounderwentabvdversusescalatedbeacoppinaresourcelimitedcountryanobservationalstudy AT udomsakbunworasate survivalratesofadultpatientswithhodgkinlymphomawhounderwentabvdversusescalatedbeacoppinaresourcelimitedcountryanobservationalstudy |